Nuvation Bio Inc.

Nuvation Bio Inc. reported second quarter 2026 financial results, with total revenue of $31.7 million, including $23.2 million in net product revenue for IBTROZI, marking a 25% quarter-over-quarter increase. The company also announced positive updated long-term Phase 2 data for safusidenib and expanded its clinical program. Despite an increased net loss of $62.8 million, Nuvation Bio strengthened its balance sheet with $661.0 million in cash, cash equivalents, and marketable securities, further boosted by $36.5 million from a convertible senior notes offering.

Nuvation Bio reported a significant increase in total revenue for the second quarter of 2026, reaching $31.69 million, primarily driven by product revenue growth. Despite the revenue surge, the company's net loss widened to $(62.84) million. The company also issued $242.62 million in convertible debt and recognized a $9.47 million loss on debt extinguishment during the period.

Nuvation Bio Inc. announced the full exercise of the underwriters' over-allotment option, resulting in the issuance of an additional $37.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032. This brings the total principal amount of Notes sold in the offering to $287.5 million. The company estimates net proceeds of approximately $277.6 million, which will be used for additional capped call transactions and general corporate purposes.

Nuvation Bio Inc. completed its registered underwritten public offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032. The offering was upsized from the previously announced $200.0 million. The company expects to use the estimated net proceeds of $241.2 million to pay for capped call transactions, repay its senior secured loan agreement in full, and for general corporate purposes. The notes have an initial conversion price of approximately $7.84 per share, representing a 35.0% premium to the last reported sale price.

Nuvation Bio Inc. reported a net income of $5.4 million for Q1 2026, a significant improvement from a $53.2 million net loss in the prior year. The company achieved $18.5 million in net product revenues for IBTROZI, with over 200 new patients starting treatment. Nuvation Bio also secured global development and commercialization rights for safusidenib by acquiring the Japan rights from Daiichi Sankyo, and presented updated positive clinical data for IBTROZI at AACR 2026.

Nuvation Bio reported a significant financial turnaround in Q1 2026, achieving a net income of $5.4 million compared to a net loss of $53.2 million in the same period last year. Total revenue dramatically increased to $83.2 million, up from $3.1 million year-over-year, driven by both new product revenue and substantial growth in collaboration and license agreements. The company also generated positive cash flow from operating activities, totaling $5.1 million.